Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
Status:
Active, not recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
To study the 2-year PFS (progression-free survival) of patients with stage III nasopharyngeal
carcinoma of pretreatment EBV DNA<4000 copy/ml treated with induction chemotherapy followed
by two different doses of intensity-modulated radiation therapy and cisplatin.